GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Apr. 15, 2021	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Finite-Lived Intangible Assets
Additions to goodwill				$ 435
Foreign currency translation impact on other intangible assets				1
Impairment of IPR&D		$ 0	$ 90	0	$ 90
Goodwill impairment		0	0	0	0
Amortization of intangible assets during the period		45	$ 47	90	$ 95
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		96		96
Other accrued liabilities | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		47		47		$ 0
Other accrued liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability						0
Other long-term liabilities | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		49		49		0
Other long-term liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability						$ 0
Life Sciences and Applied Markets
Finite-Lived Intangible Assets
Additions to goodwill				0
Diagnostics and Genomics
Finite-Lived Intangible Assets
Additions to goodwill				435
Resolution Bioscience, Inc.
Finite-Lived Intangible Assets
Additions to goodwill				435
Addition to other intangible assets				263
Acquisition
Purchase Price	$ 550
Contingent Consideration	$ 145
Resolution Bioscience, Inc. | Other accrued liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		47		47
Resolution Bioscience, Inc. | Other long-term liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		$ 49		$ 49